Byanyima, Juliana I.
Li, Xinyi
Vesslee, Sianneh A.
Kranzler, Henry R. http://orcid.org/0000-0002-1018-0450
Shi, Zhenhao http://orcid.org/0000-0001-5697-2034
Wiers, Corinde E. http://orcid.org/0000-0002-2934-8794
Funding for this research was provided by:
National Institute on Alcohol Abuse and Alcoholism (AA026892)
National Institute on Drug Abuse (DA051709, DA046345)
Article History
Accepted: 2 May 2023
First Online: 19 May 2023
Declarations
:
: Dr. Kranzler is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, Clearmind Medicine and Entheon Pharmaceuticals; a consultant to Sobrera Pharmaceuticals; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last 3 years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, Otsuka, and Pear Therapeutics; and a holder of US patent 10,900,082 titled: “Genotype-guided dosing of opioid agonists,” issued 26 January 2021. The other authors report no relevant financial interests. This work was supported by the following National Institutes of Health grants: AA026892 (Wiers), DA051709 (Shi), and DA046345 (Kranzler). Li is supported by the NIDA T32 Translational Addiction Research Fellowship Program (T32DA028874-11).
: This article does not contain any studies with human or animal subjects performed by any of the authors.